Title: Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.
Journal: Journal of medicinal chemistry20161013
Title: Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
Journal: Antimicrobial agents and chemotherapy20160701
Title: Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.
Journal: ACS medicinal chemistry letters20160609
Title: C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors.
Journal: Bioorganic & medicinal chemistry20160415
Title: Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids.
Journal: Bioorganic & medicinal chemistry letters20160415
Title: Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity.
Journal: Bioorganic & medicinal chemistry letters20160101
Title: Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.
Journal: Journal of natural products20150522
Title: Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.
Journal: European journal of medicinal chemistry20130401
Title: New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1.
Journal: Journal of medicinal chemistry20130314
Title: Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.
Journal: Journal of medicinal chemistry20120927
Title: Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
Journal: Bioorganic & medicinal chemistry letters20120815
Title: New betulinic acid derivatives as potent proteasome inhibitors.
Journal: Bioorganic & medicinal chemistry letters20111001
Title: A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.
Journal: Antimicrobial agents and chemotherapy20110701
Title: Efficient synthesis and biological evaluation of epiceanothic acid and related compounds.
Journal: Bioorganic & medicinal chemistry letters20110101
Title: HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Journal: Retrovirology20110101
Title: The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
Journal: Retrovirology20110101
Title: A fourth scale sensitive to the magnetic field; intermolecular frequency symmetry in a specific interaction between protein and low-molecular compound.
Journal: Chemical & pharmaceutical bulletin20101201
Title: Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
Journal: Antimicrobial agents and chemotherapy20101001
Title: Conjugates of betulin derivatives with AZT as potent anti-HIV agents.
Journal: Bioorganic & medicinal chemistry20100901
Title: The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
Journal: Virology20100425
Title: Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors.
Journal: Journal of medicinal chemistry20100422
Title: Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
Journal: Journal of natural products20100326
Title: High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
Journal: AIDS (London, England)20100313
Title: Can the further clinical development of bevirimat be justified?
Journal: AIDS (London, England)20100313
Title: [The role of structural protein Gag and related gene (protein) in late stages of the HIV-1 replication cycle and the inhibitors].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica20100201
Title: High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
Journal: AIDS (London, England)20100128
Title: Predicting Bevirimat resistance of HIV-1 from genotype.
Journal: BMC bioinformatics20100101
Title: Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
Journal: Retrovirology20100101
Title: [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
Journal: Voprosy virusologii20100101
Title: Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
Journal: Journal of medicinal chemistry20091210
Title: New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.
Journal: Antimicrobial agents and chemotherapy20091201
Title: Cancer preventive agents 9. Betulinic acid derivatives as potent cancer chemopreventive agents.
Journal: Bioorganic & medicinal chemistry letters20090701
Title: Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.
Journal: Journal of medicinal chemistry20090528
Title: An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
Journal: Journal of clinical pharmacology20090501
Title: [New antiretroviral drug classes in HIV therapy].
Journal: MMW Fortschritte der Medizin20090430
Title: Drug interactions with new and investigational antiretrovirals.
Journal: Clinical pharmacokinetics20090101
Title: Study may point way forward for bevirimat.
Journal: Project Inform perspective20081201
Title: Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.
Journal: AIDS clinical care20081201
Title: The absorption, distribution, metabolism and elimination of bevirimat in rats.
Journal: Biopharmaceutics & drug disposition20081001
Title: Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Journal: Clinical therapeutics20081001
Title: New drugs.
Journal: Journal of HIV therapy20080601
Title: Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
Journal: Antiviral chemistry & chemotherapy20080101
Title: The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.
Journal: Virology journal20080101
Title: The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
Journal: Antiviral therapy20080101
Title: Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinyl-betulinic acid derivatives.
Journal: Bioorganic & medicinal chemistry letters20071201
Title: Activation and inhibition of the proteasome by betulinic acid and its derivatives.
Journal: FEBS letters20071016
Title: Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
Journal: Antimicrobial agents and chemotherapy20071001
Title: Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences.
Journal: Drug metabolism and disposition: the biological fate of chemicals20070301
Title: New developments in natural products-based anti-AIDS research.
Journal: Medicinal research reviews20070101
Title: Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Journal: Clinical pharmacokinetics20070101
Title: Maturation inhibitors: a new therapeutic class targets the virus structure.
Journal: AIDS reviews20070101
Title: Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Journal: PloS one20070101
Title: The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells.
Journal: Antiviral therapy20070101
Title: Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Journal: Virology20061201
Title: Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag.
Journal: Journal of virology20061201
Title: In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Journal: Journal of virology20061101
Title: Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents.
Journal: Journal of medicinal chemistry20060907
Title: Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma.
Journal: Drug metabolism and disposition: the biological fate of chemicals20060901
Title: Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
Journal: Current opinion in investigational drugs (London, England : 2000)20060801
Title: A new assault on HIV.
Journal: Scientific American20060601
Title: 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.
Journal: Journal of virology20060601
Title: Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives.
Journal: Bioorganic & medicinal chemistry20060401
Title: 3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents.
Journal: Bioorganic & medicinal chemistry letters20041206
Title: Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.
Journal: Antimicrobial agents and chemotherapy20040201
Title: Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.
Journal: Journal of virology20040101
Title: The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid.
Journal: Retrovirology20040101
Title: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
Journal: Proceedings of the National Academy of Sciences of the United States of America20031111
Title: Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.
Journal: Antimicrobial agents and chemotherapy20010401
Title: 3,28-Di-O-(dimethylsuccinyl)-betulin isomers as anti-HIV agents.
Journal: Bioorganic & medicinal chemistry letters20010122
Title: Anti-AIDS agents 38. Anti-HIV activity of 3-O-acyl ursolic acid derivatives.
Journal: Journal of natural products20001201
Title: Synthesis and anti-HIV activity of 3-alkylamido-3-deoxy-betulinic acid derivatives.
Journal: Chemical & pharmaceutical bulletin20000901
Title: Anti-AIDS agents. 34. Synthesis and structure-activity relationships of betulin derivatives as anti-HIV agents.
Journal: Journal of medicinal chemistry19981105
Title: Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives.
Journal: Bioorganic & medicinal chemistry19971201
Title: Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
Journal: Journal of medicinal chemistry19960301
Title: Smith PF, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81.
Title: Salzwedel K, et al. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007 Jul-Sep;9(3):162-72.
Title: Martin DE, et al. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
